Press release
Postmenopausal Osteoporosis Market to Reach USD 18.5 Billion by 2034
Postmenopausal Osteoporosis
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72060
Key Takeaways
• The global postmenopausal osteoporosis market is valued at USD 10.4 billion in 2024 and is projected to reach USD 18.5 billion by 2034, expanding at a CAGR of 5.8%.
• The growing elderly female population and longer life expectancy are contributing to a sharp rise in osteoporosis cases worldwide.
• Major pharmaceutical players are investing in next-generation bone anabolic and antiresorptive agents to improve bone density and fracture prevention.
• North America currently holds the largest market share, while Asia-Pacific is anticipated to exhibit the fastest growth due to increased healthcare expenditure and diagnostic adoption.
Market Overview
Postmenopausal osteoporosis is a chronic bone disorder characterized by decreased bone mass and structural deterioration, leading to an increased risk of fractures. The condition primarily affects women aged 50 and above, resulting from estrogen deficiency following menopause.
Advances in bone biology, coupled with heightened screening rates, are fueling early detection and intervention. The market has witnessed a strong shift toward personalized therapies and digital bone-health management platforms. Moreover, increased investments in biologics, improved DEXA scan accessibility, and nationwide bone-health programs are key accelerators.
Segment Insights
• By Drug Class:
o Bisphosphonates - Remain the most widely used treatment for fracture risk reduction.
o Selective Estrogen Receptor Modulators (SERMs) - Growing popularity due to favorable safety and hormonal balance profiles.
o Calcitonin & Parathyroid Hormone Analogues - Used in moderate to severe cases.
o Monoclonal Antibodies (Denosumab, Romosozumab) - Emerging as breakthrough biologic treatments offering superior bone-density outcomes.
• By Route of Administration:
o Oral - Dominates due to ease of administration.
o Injectable - Expanding rapidly due to improved patient adherence and biologic therapies.
• By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
• By Region:
o North America - Leads globally with high awareness and access to specialty care.
o Europe - Benefits from government-supported fracture prevention initiatives.
o Asia-Pacific - Poised for rapid growth with aging demographics and increased healthcare access.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=72060
Recent Developments
• Amgen Inc. expanded its osteoporosis portfolio through global rollout of Evenity (romosozumab), a bone-forming monoclonal antibody.
• Eli Lilly and Company strengthened its biologics pipeline with next-generation sclerostin inhibitors targeting postmenopausal bone loss.
• UCB Pharma advanced late-stage trials for novel anabolic compounds with dual bone-formation and antiresorptive effects.
• Governments in Japan, South Korea, and the EU have introduced nationwide osteoporosis screening programs targeting postmenopausal women.
• Pharmaceutical alliances are driving digital adherence solutions, such as mobile-based reminders and patient-monitoring platforms.
Expert Insight
"The postmenopausal osteoporosis market is entering an innovation phase powered by biologics and preventive care strategies. With digital diagnostics, personalized risk assessment, and hormone-linked therapies, patient outcomes are improving faster than ever before," said the healthcare research team at Exactitude Consultancy.
Market Drivers
• Rising global population of postmenopausal women.
• Increasing adoption of biologics and next-generation anabolic agents.
• Government awareness campaigns promoting early screening.
• Growing focus on fracture prevention and long-term bone health.
• Integration of digital health tools for monitoring bone density.
Market Challenges
• High cost of biologics and limited access in low-income regions.
• Low treatment adherence due to asymptomatic disease progression.
• Limited diagnostic access in rural healthcare systems.
• Safety concerns over long-term bisphosphonate use.
Explore Full Report here: https://exactitudeconsultancy.com/reports/72060/postmenopausal-osteoporosis-market
Government and Policy Initiatives
Several health ministries and international organizations are focusing on preventive bone health. Programs encouraging DEXA scans for women over 50 are expanding across Europe, North America, and Asia-Pacific. Reimbursement support for biologic treatments and fracture management has improved accessibility, while partnerships between public health bodies and pharma companies are enhancing patient education and screening outreach.
Market Forecast
Between 2024 and 2034, the postmenopausal osteoporosis market is forecast to grow at a CAGR of 5.8%, reaching USD 18.5 billion by 2034. The strongest growth will come from biologic therapies, digital diagnostic integration, and healthcare expansion in emerging economies.
Conclusion
The global postmenopausal osteoporosis market is set for significant advancement as science, technology, and healthcare policy converge to address bone health in aging women. With biologic breakthroughs, improved screening, and enhanced patient compliance strategies, the market is well-positioned for sustained expansion throughout the forecast period.
This report is also available in the following languages : Japanese (閉経後骨粗鬆症市場), Korean (폐경 후 골다공증 시장), Chinese (绝经后骨质疏松症市场), French (Marché de l'ostéoporose postménopausique), German (Markt für postmenopausale Osteoporose), and Italian (Mercato dell'osteoporosi postmenopausale), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/72060/postmenopausal-osteoporosis-market#request-a-sample
Related Reports by Exactitude Consultancy
Osteoporosis Market
https://exactitudeconsultancy.com/reports/71004/osteoporosis-market
Postmenopausal Vaginal Atrophy Market
https://exactitudeconsultancy.com/reports/70738/postmenopausal-vaginal-atrophy-market
Phytoestrogen Supplements Market
https://exactitudeconsultancy.com/reports/51817/phytoestrogen-supplements-market
Bone Cement for Vertebral Market
https://exactitudeconsultancy.com/reports/57216/global-bone-cement-for-vertebral-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Postmenopausal Osteoporosis Market to Reach USD 18.5 Billion by 2034 here
News-ID: 4257292 • Views: …
More Releases from Exactitude Consultancy
Nanoparticle Formulation Market to Grow at 8.9% CAGR from 2025 to 2034
Subheadline:
Advances in nanotechnology, gene therapy, and precision drug delivery systems are reshaping global pharmaceutical manufacturing and driving robust growth in the nanoparticle formulation market.
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/72422
Introduction
The Nanoparticle Formulation Market is at the forefront of next-generation therapeutics, propelled by breakthroughs in nanomedicine, controlled drug release, and targeted therapy delivery.
Valued at USD 10.5 billion in 2024, the market is projected to reach USD 24.8 billion…
Lymphedema Market Poised for Robust Growth Through 2034 Amid Rising Awareness an …
Pune, India - November 2025 - According to a new report by Exactitude Consultancy, the global Lymphedema Market is set to witness significant growth in the coming decade, propelled by early diagnosis initiatives, expanding therapeutic options, and increased adoption of compression and physiotherapy devices. The market's evolution reflects a strong convergence of healthcare innovation, patient education, and government support programs.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72055
Key Takeaways
• The…
Somatotropin Deficiency Market to Exhibit Steady Growth Through 2034 as Novel Th …
Market forecast shows a compound annual growth rate (CAGR) of approximately 4.4% from 2024 to 2034, driven by technological advances and expanding adult patient coverage.
Pune, India - November 2025 - Exactitude Consultancy reports that the global Somatotropin (Growth Hormone) Deficiency Market is poised for consistent expansion over the next decade. Rising prevalence of growth hormone deficiency (GHD), greater diagnostic accuracy, and innovative long-acting therapies are transforming this highly specialized endocrine…
Vitreous Enamel Panel (VE Panel) Market to Grow at 6.7% CAGR, Reaching USD 2.47 …
Snippet:
The Vitreous Enamel Panel (VE Panel) Market is gaining strong momentum as modern architects and infrastructure developers turn to durable, fire-resistant, and aesthetic wall-cladding materials. With leading manufacturers like AUE, TGP, and CELSA Group innovating in sustainable enamel coating technologies, the VE Panel industry is poised for substantial growth through 2034.
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/75478
What Are Vitreous Enamel Panels (VE Panels)?
Vitreous enamel panels are metal…
More Releases for Postmenopausal
Postmenopausal Osteoporosis Market Massive Growth opportunity Ahead
Introduction
Postmenopausal osteoporosis is one of the most common metabolic bone disorders, characterized by reduced bone density and increased fracture risk due to declining estrogen levels following menopause. Affecting 1 in 3 women over age 50 worldwide, it is a major cause of morbidity, disability, and healthcare costs. Hip, spine, and wrist fractures associated with osteoporosis contribute significantly to reduced quality of life and increased mortality rates among elderly women.
While calcium…
Key Trends Reshaping the Postmenopausal Vaginal Atrophy Treatment Market: Advanc …
"Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Postmenopausal Vaginal Atrophy Treatment Market Size Growth Forecast: What to Expect by 2025?
The market size for treating postmenopausal vaginal atrophy has seen significant growth recently. The market is projected to increase from $2.1 billion in 2024 to $2.28 billion in 2025, reflecting a compound annual growth rate (CAGR)…
Rising Prevalence Of Osteoporosis Spurs Momentum In Postmenopausal Osteoporosis …
The Postmenopausal Osteoporosis Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Current Postmenopausal Osteoporosis Treatment Market Size and Its Estimated Growth Rate?
The market for treatment of postmenopausal osteoporosis has seen a steady increase in size over the recent years. It's projected…
Postmenopausal Osteoporosis Market Size Unlocking New Opportunities for Success
The global postmenopausal osteoporosis market was valued at USD 9.7 billion in 2023 and is projected to reach USD 15.3 billion by 2032, growing at a compound annual growth rate (CAGR) of 5.90% from 2024 to 2032.
Request a sample copy of this report at: https://www.omrglobal.com/request-sample/postmenopausal-osteoporosis-market
Postmenopausal Osteoporosis Market Overview:
The postmenopausal osteoporosis market is driven by the increasing prevalence of osteoporosis in postmenopausal women due to hormonal changes that reduce bone density.…
Postmenopausal Vaginal Atrophy - Drug Pipeline Landscape, 2022
Vaginal Atrophy is a condition in which vagina gets drier and thinner and inflammation of the Vaginal walls may occur when the body has less estrogen. Vaginal Atrophy in which Vaginal refers to the vagina while Atrophy means wasting away or diminution occurs most often after menopause. For Many women, Vaginal Atrophy not only makes intercourse painful but also leads to distressing urinary symptoms
Read more about Postmenopausal Vaginal Atrophy's pipeline,…
Postmenopausal Osteoporosis Market Share, Trends and Forecast to 2023
The postmenopausal osteoporosis market is expected to grow significantly during the forecast period (2018-2023). Osteoporosis is a skeletal disorder characterized by skeletal fragility, microarchitectural disruption, and low bone mass. It is a condition where the bone density and bone mass decreases and in the long run increases the risk of bone fracture. The global postmenopausal osteoporosis market is significantly growing due to some factors which include increasing geriatric population. Age…
